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Background. This study was conducted to compare and evaluate the effect of adding lornoxicam or nitroglycerine as adjuncts to
lidocaine in intravenous regional anesthesia (IVRA). Methods. 60 patients were randomly separated into three groups, lidocaine
group (group L), lidocaine + lornoxicam group (group LL), and lidocaine + lornoxicam + transdermal nitroglycerine group (group
LL-N). Hemodynamic parameters, sensory and motor blocks onset, and recovery times were recorded. Analgesic consumption
for tourniquet pain and postoperative period were recorded. Results. Sensory block onset times and motor block onset times were
shorter in the LL-N and LL groups compared with L group. Sensory block recovery time and motor block recovery time were
prolonged in the LL and LL-N groups compared with group L. The amount of fentanyl required for tourniquet pain was less in
group LL and group LL-N when compared with group L. VAS scores of tourniquet pain were higher in group L compared with the
other study groups. Postoperative VAS scores were higher for the first 4 hours in group L compared with the other study groups.
Conclusion. The adjuvant drugs (lornoxicam or TNG) when added to lidocaine in IVRA were effective in improving the overall
quality of anesthesia, reducing tourniquet pain, increasing tourniquet tolerance, and improving the postoperative analgesia.
1. Introduction
Intravenous regional anesthesia (IVRA) is widely recom-
mended and applied in patients undergoing ambulatory
procedures. Various additives have been used with local
anesthetic agents to improve block quality, reduce tourniquet
pain, and prolong postdeflation analgesia [1]. The poten-
tial intraoperative benefit ofnonsteroidal anti-inflammatory
drugs (NSAIDS) added to local anesthetic agents have been
demonstrated at several studies [2, 3]. Lornoxicam is a new
NSAID of the oxicam class which is available in oral and
parenteral forms. It is a nonopioid analgesic as effective
as morphine, tramadol, and meperidine and produces less
adverse effects than others [4]. Transdermal nitroglycerine
(TNG), nitric oxide generator, helps in distribution of local
anesthetic agents to neuron trunks by vasodilatation and also
it has been demonstrated that, when transdermal nitroglyc-
erine is used with other drugs, analgesic effect is increased.
Nitric oxide and NSAI drug combinations are produced. It
is called (NONSAID) for reducing adverse effects of NSAI
drugs which are caused by COX enzyme inhibition [5–9].
This study was designed to compare and evaluate the effect of
adding lornoxicam or both lornoxicam and TNG as adjuncts
to lidocaine for IVRA.
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2. Methods
With hospital ethics committee approval and informed writ-
ten consent, we recruited 60 nonpremedicated ASA physical
status I-II 18- to 40-year-old patients undergoing elective
hand, wrist, and forearm surgery procedures. Patients with
Raynaud’s disease, sickle cell anemia, and history of drug
allergies were excluded from the study.
The study design was randomized and double-blinded.
An anesthesia assistant who was blinded to study pre-
pared identical syringes containing each drug according to
randomisation list. At premedication room, two cannulae
were placed; 22-gauge cannula was placed in dorsal vein of
operative hand for applying study drugs; and other cannulae
was placed in the opposite hand for fluid 5% ringer lactate
infusion administration.
Monitoring includes measurement of arterial blood pres-
sure (mean arterial pressure (MAP)), heart rate (HR), and
saturation of peripheral oxygen (SpO
2
) (Taema Artema
MM206, Artema Medical AB Sundbyberg, Sweden). After
application of standard monitoring, operative arm was ele-
vated for two minutes and was then exsanguinated with
an Esmarch bandage from distal to proximal. We placed
a pneumatic tourniquet which has double cuff around the
upper arm. Proximal cuff was inflated to 250mmHg, and
distal tourniquet was not inflated. Circulatory isolation of the
arm was verified by inspection, absence of radial pulse, and
loss of pulse oximetry racing in the ipsilateral index finger.
The tourniquet period was from the time at which the distal
cuff was inflated to the time the patient experienced pain.
The syringes contained 3mg/kg lidocaine 2% (Aritmal,
TEMS, Istanbul, Turkey) diluted with saline to a total volume
of 40mL in all groups for IVRA.
Patients were randomized to three groups with 20
patients in each.
Group I (Group L) (Lidocaine Group). 3mg/kg lidocaine 2%
(Aritmal, TEMS, Istanbul, Turkey) was diluted with saline
to a total volume of 40mL. Two hours before the operation,
empty TNG flaster (Nitroderm, TTS flaster, Novartis) was
placed on the hand at which the operation would be per-
formed.
Group II (Group LL) (Lidocaine + Lornoxicam Group).
3mg/kg lidocaine 2% (Aritmal, TEMS, Istanbul, Turkey) was
diluted with saline to a total volume of 40mL and also 8mg
lornoxicam (Xefo, Abdi Ibrahim, Turkey) was added to the
solution. Two hours before the operation, empty TNG flaster
(Nitroderm, TTS flaster, Novartis) was placed at the hand at
which the operation would be performed.
Group III (Group LL-N) (Lidocaine + Lornoxicam + TNG
Group). 3mg/kg lidocaine 2% (Aritmal, TEMS, Istanbul,
Turkey) was diluted with saline to a total volume of 40mL
and also 8mg lornoxicam (Xefo, Abdi Ibrahım, Turkey) was
added to the solution. Two hours before the operation, TNG
flaster which contains 5mg nitroglycerine (Nitroderm, TTS
flaster, Novartis) was placed at the surgical site.
The study solutions were injected over 90 seconds by an
anesthesiologist blinded to the study drugs.
After IVRA was achieved, sensory block was assessed by
a pinprick testing performed with a 22-gauge short-beveled
needle. Patient response was evaluated in the dermatomal
sensory distribution of ulnar, median, and radial nerves.
Sensory block onset time was noted as the time elapsed
from injection of study drug to sensory block achieved in all
dermatomes.
Motor function was assessed by asking the subjects to flex
and extend his/her wrist and fingers, and complete motor
block was noted when no voluntary movement was possible.
Motor block onset time was the time elapsed from injection
of the study drug to complete motor block.
After sensorial and motor blocks were assessed at all
dermatomes, distal cuff was inflated to 250 mmHg, and
proximal cuff was deflated after taking out TNG patch.
Pain due to the tourniquet was assessed with a 10 cm visual
analogue scale (VAS) (0 = no pain and 10 cm = worst pain
imaginable). HR, MAP, SPO2, and VAS were monitored and
recorded before and after the application of the tourniquet
and 1, 5, 15, 30, and 45 minutes after the injection of local
anesthetic solution.
If the patient reportedVAS> 3 during the surgery, 1 𝜇g/kg
IV fentanyl (fentanyl citrate; Abbott, North Chicago, IL)
was given. Total fentanyl requirement (dose and time) was
recorded.
During the surgery time, 4mg IV ondansetron hydro-
chloride (Zofran, GlaxoSmith Kline) was given for nausea
and vomiting, 5mg IV ephedrine was given for hypotension
(systolic arterial blood pressure < 90mmHg or 50mmHg
lower than the normal value), and 0.5mg IV atropine was
given for bradycardia (HR < 50/min). All of these complica-
tions were also recorded with respect to time.
After the surgery, the anesthesiologist, who did not know
what medication was given by TNG patch and injection, was
asked to qualify the anesthetic conditions according to the
following numeric scale.
At the end of the operation the patients were asked to
qualify the operative conditions such as tourniquet pain or
incisional pain according to the following numeric scale.
Excellent (4) = no complaint from pain.
Good (3) = minor complaint with no need for
supplemental analgesics.
Moderate (2) = complaint which required supple-
mental analgesic.
Unsuccessful (1) = patient given general anesthesia.
At the end of the surgery, the surgeon, who was blind
to patient group, was asked to score operative conditions
such as disturbing movement of arm and excessive bleeding
according to the following numeric scale [10]:
0 = unsuccessful;
1 = poor;
2 = acceptable;
3 = good;
4 = excellent.
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Table 1: Patients demographics data, duration of tourniquet, and surgery time.
Group L (𝑛 = 20) Group LL (𝑛 = 20) Group LL-N (𝑛 = 20) p1 p2 p3
Age (years) 47.70 ± 3.26 55.70 ± 2.38 51.30 ± 3.17 0.063 0.43 0.28
Gender (M/F) 14/16 16/14 17/13 0.67 0.66 0.38
Weight (kg) 76.20 ± 1.96 76.70 ± 2.4 73.20 ± 3.12 0.88 0.42 0.401
Height (cm) 161 ± 7 162 ± 6 161 ± 5 0.13 0.15 0.23
Tourniquet time (min) 43.00 ± 4.73 39.30 ± 3.51 39.50 ± 3.86 0.53 0.57 0.97
Surgery time (min) 35.10 ± 4.00 33.80 ± 3.60 34.50 ± 3.58 0.81 0.91 0.89
(Values are mean ± SD); p1: comparison of groups L and LL; p2: comparison of groups L and LL-N; and p3: comparison of groups LL and LL-N.
Table 2: Onset and recovery times of sensory and motor blocks (min).
Group L (𝑛 = 20) Group LL (𝑛 = 20) Group LL-N (𝑛 = 20) p1 p2 p3
Sensory block onset time
(min) 6.20 ± 0.33 5.10 ± 0.38 3.40 ± 0.31 0.041 0.001 0.003
Sensory block recovery
time (min) 3.10 ± 0.53 7.60 ± 0.72 8.90 ± 0.77 0.001 0.001 0.23
Motor block on set time
(min) 11.3 ± 1.5 8.4 ± 1.6 4.7 ± 0.82 0.67 0.25 0.15
Motor block recovery time
(min) 7.1 ± 1.2 8.4 ± 1.4 7.9 ± 1.2 0.001 0.001 0.1
(Values are mean ± SD); p1: comparison of groups L and LL; p2: comparison of groups L and LL-N; and p3: comparison of groups LL and LL-N.
The tourniquet was not deflated before 30 minutes and was
not inflated more than 2 hours. At the end of surgery, the
tourniquet deflation was performed by the cyclic deflation
technique. After tourniquet deflation, sensory recovery time
(the time elapsed after tourniquet deflation up to recovery of
pain in all innervated areas determined by pinprick test done
every 30 seconds) was noted. Motor block recovery time (the
time elapsed after tourniquet deflation up to movement of
fingers) was noted. First analgesic requirement time (the time
elapsed after tourniquet release to the first patient request of
analgesic) was also noted.
Nausea, vomiting, skin reactions, dizziness, tinnitus,
tachycardia, bradycardia, hypotension, and hypertension
were noted until discharge from the recovery room and at the
end of the 24 h postoperative observation period.
IM diclofenac (Voltaren; Ciba-Geigy, I˙stanbul, Turkey)
75mg was given to patients with a VAS > 3 at postoperative
first 8 hours and total diclofenac requirements (time and
amount) were recorded by a blinded anesthesia resident.
Patients were instructed to take one peroral paracetamol
(Parol tablet 500mg; Atabay) tablet at postoperative 8–24
hours required for a VAS > 3 while at home. All the patients
were called by telephone the day after surgery by a blinded
observer.The time from tourniquet deflation until the patient
first required analgesic, diclofenac im or/and peroral parac-
etamol, was noted at the first postoperative 24-hour period.
2.1. Statistical Analysis. The statistical evaluation was done
using SPSS 17.0 for Eindows (SPSS Inc., Chicago, IL, USA).
Initial sample size estimation showed that approximately 18
patients were needed in each group to detect a clinically
relevant reduction of fentanyl consumption by 25% and
also approximately 50% clinically significant changes of the
sensory block onset and recovery times with a power of 80%
and a level of significance of 5%. Independent samples 𝑡-test
was used for evaluation of the demographic data, hemody-
namic data, the time of sensory and motor block onset and
the recovery time, duration of surgery and tourniquet, initial
time of tourniquet pain, VAS scores, postoperative first anal-
gesic requirement time, and intraoperative and postoperative
analgesic use. Mann-Whitney 𝑈 test was used for intraoper-
ative and postoperative quality of anesthesia. Level of signif-
icance was determined at 𝑃 > 0.05 for no statistically signifi-
cant difference and at 𝑃 < 0.05 for significant difference.
3. Results
Demographic data of the groups were similar to mean age,
weight, height, and sex ratio (Table 1). All patients were
able to complete the study, and there were no exclusions in
data analysis. There were no statistical differences between
groups’ duration of surgery and tourniquet time (Table 1).
Sensory block onset times were shorter in the LL-N (3.4 ±
0.31 minutes) and LL (5.10 ± 0.38 minutes) groups compared
with group L (6.2± 0.33minute) (𝑃 < 0.001) andmotor block
onset times were shorter in the group LL (8.4 ± 1.6 minutes)
and group LL-N (4.7 ± 1.2 minutes) compared with group L
(11.2 ± 1.5 minutes) (𝑃 < 0.0001). Sensory block recovery
time was prolonged in the LL (7.6 ± 0.72 minutes) and LL-
N (8.9 ± 0.77 minutes) groups compared with group L (3.1 ±
0.53 minutes) (𝑃 = 0.001). Motor block recovery time was
prolonged in the LL (8.4 ± 1.4 minutes) and LL-N (7.9 ± 1.2
minutes) groups compared with group L (7.1 ± 1.2 minutes)
(𝑃 = 0.0014 and 0.023, resp.) (Tables 2 and 3). The number
of patients who need additional fentanyl requirements were
significantly more in group L than the other two groups
(𝑃 = 0.047), but amount of fentanyl required for tourniquet
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Table 3: Initial time of tourniquet pain (min).
Group L (𝑛 = 20) Group LL (𝑛 = 20) Group LL-N (𝑛 = 20) p1 p2 p3
Initial time of tourniquet
pain (min) 15.80 ± 5.41 7.00 ± 4.90 3.00 ± 3.00 0.24 0.009 0.17
(Values are mean ± SD); p1: comparison of groups L and LL; p2: comparison of groups L and LL-N; and p3: comparison of groups LL and LL-N.
Table 4: Total amount of fentanyl, diclofenac, and paracetamol requirement (𝜇g).
Group L (𝑛 = 20) Group LL (𝑛 = 20) Group LL-N (𝑛 = 20) p1 p2 p3
Total amount of fentanyl requirement (𝜇g) 51 ± 61 15 ± 32 7 ± 22 0.047 0.017 0.15
Diclofenac requirement (mg)—postoperative first 8 hour 60 ± 31 37 ± 39 45 ± 38 0.11 0.35 0.67
Paracetamol requirement (mg)—postoperative 24 hours 850 ± 579 450 ± 497 100 ± 210 0.17 0.001 0.55
(Values are mean ± SD); p1: comparison of groups L and LL; p2: comparison of groups L and LL-N; and p3: comparison of groups LL and LL-N.
pain was statistically similar in all groups (Table 4).There was
also no statistical difference among groups when compared
for MAP, HR, and SPO2 at any time either intraoperative or
postoperative time (data are presented in Table 5) (𝑃 > 0.05).
At the first 8 hours of postoperative period, the number of
patients who need additional diclofenac and diclofenac con-
sumption was statistically not different between the groups.
Both the number of patients who need additional parac-
etamol and paracetamol amount which was used at post-
operative (8–24 h) period were statistically more at group L
than the other two groups. There was significant difference
in paracetamol requirement between the groups L and LL-N
(𝑃 = 0.001).
No patient suffered from incisional pain during intraop-
erative period in all groups. VAS scores of tourniquet pain
were higher at 10, 20, 30, and 40minutes in group L compared
with the other study groups (𝑃 < 0.0001). Postoperative VAS
scores were higher for the first 4 h in group L compared with
the other study groups (𝑃 < 0.0001) (Table 6). Anesthesia
quality, determined by anesthesiologist and the patient, was
better in groups LL and LL-N than in group L (𝑃 < 0.0001)
(Table 7). There was not any significant difference in side
effects between the groups (𝑃 > 0.05).
4. Discussion
Themain result of our study revealed that the addition of both
lornoxicam and nitroglycerin during IVRA improved speed
of sensory andmotor block onset times, decreased tourniquet
pain, improved quality of anesthesia, and decreased intra-
operative and postoperative analgesic consumption without
causing any side effects.
Intravenous regional anesthesia (IVRA) is a simple,
common, and a reliable method which provides adequate
anesthesia and muscle relaxation at short operative proce-
dures of extremity surgery. Lidocaine is the most commonly
chosen local anesthetic for IVRA. But, there are well-known
limitations to this local anesthetic especially at prolonged
surgery and postoperative period.
Various additives have been used with local anesthetics to
improve block quality, reduce tourniquet pain, and prolong
postdeflation analgesia and varying results with the possibil-
ity of additional complications have occurred. Additives used
were opioids (fentanyl, meperidine, morphine, and sufen-
tanil), tramadol, NSAIDs (ketorolac, tenoxicam, lornoxicam,
and acetylsalicylate), clonidine, dexmedetomidine, nitro-
glycerine, muscle relaxants (atracurium, pancuronium, and
mivacurium), alkalization with sodium bicarbonate and
potassium [1, 10–14].
NSAIDs inhibit the production of prostaglandins from
arachidonic acid in phospholipid membranes. The result is
decreased afferent nociceptive signal arising from the site of
surgery and also they act at peripheral nociceptors, perhaps
by interfering with the synthesis and activity of pain medi-
ators derived from arachidonic acid, and can supplement
postoperative pain relief. NSAIDs as a part of IVRA have
longer analgesic benefit than the same dose parenterally
administered [1, 15].
Lornoxicam (chlortenoxicam) is a nonselective NSAID
of the oxicam class, with analgesic, anti-inflammatory, and
antipyretic effects. It is a highly potent short acting analgesic
agent. It is available in oral and parenteral forms. It is
separated from established oxicams by a relatively short
elimination half-life (3 to 5 hours); this may be suggested
as advantageous for use in postoperative period and also
advantageous due to tolerability. In particular, it has a tolera-
bility profile characteristics of NSAIDs, with gastrointestinal
disturbances (pain, dyspepsia, nausea, and vomiting) being
themost remarkable events. Lornoxicam is highly effective in
both relieving postoperative pain and reducing the need for
rescue analgesics following different surgical procedures [4,
15–23]. The beneficial effect of lornoxicam on postoperative
pain relief in our study was clinically evident by lower pain
scores and longer time to diclofenac rescue request with a
reduction in the first 8- and 24-hour analgesic consumption,
but it is not statistically evident [19].
Sen and colleagues show that addition of NSAID
(lornoxicam) to lidocaine for IVRA shortens the onset of
sensory and motor block, decreases tourniquet pain, and
improves postoperative analgesia without causing any side
effects. In another study, they add NSAID (ketorolac) to lido-
caine for IVRA and they conclude that ketorolac improves
IVRA with lidocaine in terms of controlling intraoperative
tourniquet pain by diminishing postoperative pain [16].
NSAIDs as a part of IVRA have longer analgesic benefit
than the same dose parenterally administered [1]. We have
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Table 6: Intraoperative tourniquet pain and postoperative VAS scores.
Group L (𝑛 = 20) Group LL (𝑛 = 20) Group LL-N (𝑛 = 20)
5 minutes after tourniquet inflation 1 (0-1) 1 (0-1) 1 (0-1)
15 minutes after tourniquet inflation 1 (0-1) 1 (0-1) 1 (0-1)
30 minutes after tourniquet inflation 2 (0−3) 1 (0−2) 1 (0−3)
45 minutes after tourniquet inflation 3 (2−5) 2 (1−3) 3 (2−4)
5 minutes after tourniquet release 3 (2−5) 2 (2−5) 2 (2−4)
30 minutes after tourniquet release 4 (3−5) 3 (3−5) 3 (2−5)
2 h after tourniquet release 4 (3−5) 3 (3−5) 3 (2−5)
VAS scores of tourniquet pain were higher at 10, 20, 30, and 40 minutes in group L compared with the other study groups (𝑃 < 0.0001). Postoperative VAS
scores were higher for the first 4 hours in group L compared with the other study groups (𝑃 < 0.0001).
Table 7: Quality of anesthesia assessed by anesthesiologists and surgeons.
Group L (𝑛 = 20) Group LL (𝑛 = 20) Group LL-N (𝑛 = 20)
Quality of anesthesia (patient) 3 (2–4) 4 (3-4)∗ 4 (3-4)∗
Quality of anesthesia (surgeon) 2 (2-3) 4 (3-4)∗ 3 (3-4)∗
(Values are mean ± SD).
∗
𝑃 < 0.05 in comparison with control group.
drawn a similar conclusion in our study both shorter sensory
and motor block onset times and longer sensory and motor
recovery times that received lidocaine plus lornoxicam than
only lidocaine group.This result can be explained by the effect
of alkalization. Alkalization with bicarbonate as an adjunct
for IVRA is used widely. By alkalization, it is possible to
increase the amount of free base LA; this helps in the nerve
penetration easily and onset of blockade faster. The pH of
lornoxicam intravenous form is approximately 8.7, the pH
of the lidocaine solution is 6.7, and the pH of lornoxicam-
lidocaine mixture is 7.6 [17].
NTG shows its analgesic effect as it is metabolized to
nitric oxide (NO). NO causes an increase, in the intracellular
concentration of cyclic guanosine monophosphate (c-GMP),
which produces pain modulation in the central and periph-
eral nervous system [5, 24, 25]. The injected LA diffuses into
the small veins surrounding the nerves and then into the
vasa nervorum and capillary plexus of the nerves, leading
to a core-to-mantle (centrifugal) conduction block in the
nerves involved. It then spreads around the small nerves in
the skin, blocking their conduction. Several studies on NTG
have demonstrated its analgesic effect in acute and chronic
pain conditions. Berrazueta et al. proved the analgesic action
of transdermal glycerylnitrate in the treatment of shoulder
pain [8]. Lauretti et al. documented that transdermal NTG
enhanced the postoperative analgesic effect of spinal sufen-
tanil and neostigmine [7]. Also NTG has been studied as
an adjuvant to IVRA. Abbasivash et al. studied the effect of
adding NTG to lidocaine in IVRA where it shortened the
onset times of sensory and motor block and decreased the
tourniquet and postoperative pains, without any side effect
[26]. Sen et al. studied the addition of NTG to lidocaine in
IVRA where it shortened sensory and motor block onset
times, prolonged sensory and motor block recovery times,
and improved tourniquet pain while prolonging the time
for the first analgesic requirement and decreasing the total
amount of postoperative analgesic requirement without side
effects [15]. Turan et al. suggested that transdermal NTG has
useful effects on sensory andmotor block without side effects
in IVRA [27]. Our results seem to be similar to those of
Abbasivashi et al. and Sen et al. Sensory and motor block
onset times were statistically shorter in group LL-N than in
group LL and group L. This could be explained by direct
vasodilator effect of nitroglycerine that promotes distribution
of lidocaine to nerves. There were also lower VAS scores
for tourniquet pain and reduced paracetamol requirement
time in group NTG. In our study, there was no significant
difference in side effects between the three groups; this can
be due to the fact that nitroglycerin produces antioxidative
effect [27]. In that respect, the antioxidative effects of the drug
might be particularly important for preventing gastrointesti-
nal side effects. Transdermal nitroglycerin patch may, in fact,
reduce gastric damage induced by parenteral administration
of indomethacin [28]. It was also demonstrated that nitric
oxide-releasing NSAIDs (NONSAID) can prevent gastroin-
testinal side effects in acute and chronic administration
in animals. Sen et al. suggests that lornoxicam may cause
gastrointestinal and renal side effects. Adding nitroglycerin
to lornoxicam might prevent gastrointestinal and renal side
effects compared to lornoxicam alone [16].
In conclusion, addition of lornoxicam or TNG to lido-
caine in IVRAwas effective in improving the overall quality of
anesthesia, reducing tourniquet pain, increasing tourniquet
tolerance, and improving the postoperative analgesia. The
combination of lidocaine, lornoxicam, and TNG as an adju-
vant produced faster onset of sensory andmotor blockades in
comparison to other groups.The underlying mechanisms are
yet to be elucidated with more experimental studies.
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